Skip to main content

Mediterranean Diet May Modestly Reduce Risk for Obesity-Related Cancers

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 27, 2025.

By Lori Solomon HealthDay Reporter

THURSDAY, Feb. 27, 2025 -- Higher adherence to the Mediterranean diet (MedDiet) is associated with a modest reduction in the risk for obesity-related cancers (ORCs), according to a study published online Feb. 25 in JAMA Network Open.

Inmaculada Aguilera-Buenosvinos, Ph.D., from the University of Navarra in Spain, and colleagues examined the association between adherence to the MedDiet and the risk for ORCs. The analysis included data from 450,111 participants (mean age, 51.1 years) in the European Prospective Investigation Into Cancer and Nutrition study.

The researchers found that during a median 14.9 years of follow-up, 4.9 percent of participants experienced an ORC (rates, 0.053, 0.049, and 0.043 per person-year in the low, medium, and high MedDiet adherence groups, respectively). Compared with low MedDiet adherence (0 to 3 points), participants with high adherence to the MedDiet (7 to 9 points) had a lower risk for ORC (hazard ratio, 0.94). A similar inverse association was seen for participants with medium adherence (4 to 6 points) compared with low adherence.

"Our mediation analysis did not show waist-to-hip ratio or body mass index as mediators between MedDiet and ORC risk, possibly due to the low prevalence of obesity in our cohort and the distinct contribution of general versus abdominal obesity to metabolic disruptions," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted February 2025

Read this next

Red Wine No Better Than White in Terms of Cancer Risk

THURSDAY, March 13, 2025 -- There is no significant difference in the association between red or white wine consumption and overall cancer risk, according to a meta-analysis...

No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery

WEDNESDAY, March 12, 2025 -- Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter...

ASTRO Issues Clinical Guideline for Use of Radiation Therapy in Anal Cancer

WEDNESDAY, March 12, 2025 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in Practical Radiation Oncology...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.